Finding the place of histone deacetylase inhibitors in prostate cancer therapy

Deborah L. Marrocco-Tallarigo, Margaret M. Centenera, Howard I. Scher, Wayne D. Tilley, Lisa M. Butler

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological malignancies and solid tumors. In the case of prostate cancer, HDACIs are effective at inhibiting proliferation and inducing apoptosis in a range of in vitro and in vivo experimental models. Recent studies have revealed that the actions of HDACIs in prostate cancer cells extend beyond regulation of histone acetylation and affect proteins involved in maintaining cellular homeostasis and tumor progression, including the androgen receptor, p21WAF1 and VEGF. The broad spectrum of HDACI targets has allowed rational design of combinations with other therapeutic agents to target multiple pathways involved in prostate cancer progression, including angiogenesis and androgen signaling. In particular, synergistic inhibition of prostate cancer cell growth has been demonstrated using HDACIs in combination with radio- and chemo-therapy, Apo2L/TRAIL, angiogenesis inhibitors, heat-shock protein 90 inhibitors and androgen receptor antagonists. This review examines the current understanding of the actions of HDACIs in prostate cancer cells, both in a laboratory and a clinical context and discusses the potential utility of combination strategies for the treatment of prostate cancer.

LanguageEnglish
Pages619-630
Number of pages12
JournalExpert Review of Clinical Pharmacology
Volume2
Issue number6
DOIs
Publication statusPublished - 1 Dec 2009

Keywords

  • Androgen signaling
  • Clinical trials
  • Combination therapies
  • Histone deacetylase inhibitors
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Marrocco-Tallarigo, Deborah L. ; Centenera, Margaret M. ; Scher, Howard I. ; Tilley, Wayne D. ; Butler, Lisa M. / Finding the place of histone deacetylase inhibitors in prostate cancer therapy. In: Expert Review of Clinical Pharmacology. 2009 ; Vol. 2, No. 6. pp. 619-630.
@article{ce9d133697f0464bb828ecade815395c,
title = "Finding the place of histone deacetylase inhibitors in prostate cancer therapy",
abstract = "Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological malignancies and solid tumors. In the case of prostate cancer, HDACIs are effective at inhibiting proliferation and inducing apoptosis in a range of in vitro and in vivo experimental models. Recent studies have revealed that the actions of HDACIs in prostate cancer cells extend beyond regulation of histone acetylation and affect proteins involved in maintaining cellular homeostasis and tumor progression, including the androgen receptor, p21WAF1 and VEGF. The broad spectrum of HDACI targets has allowed rational design of combinations with other therapeutic agents to target multiple pathways involved in prostate cancer progression, including angiogenesis and androgen signaling. In particular, synergistic inhibition of prostate cancer cell growth has been demonstrated using HDACIs in combination with radio- and chemo-therapy, Apo2L/TRAIL, angiogenesis inhibitors, heat-shock protein 90 inhibitors and androgen receptor antagonists. This review examines the current understanding of the actions of HDACIs in prostate cancer cells, both in a laboratory and a clinical context and discusses the potential utility of combination strategies for the treatment of prostate cancer.",
keywords = "Androgen signaling, Clinical trials, Combination therapies, Histone deacetylase inhibitors, Prostate cancer",
author = "Marrocco-Tallarigo, {Deborah L.} and Centenera, {Margaret M.} and Scher, {Howard I.} and Tilley, {Wayne D.} and Butler, {Lisa M.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1586/ecp.09.44",
language = "English",
volume = "2",
pages = "619--630",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "6",

}

Finding the place of histone deacetylase inhibitors in prostate cancer therapy. / Marrocco-Tallarigo, Deborah L.; Centenera, Margaret M.; Scher, Howard I.; Tilley, Wayne D.; Butler, Lisa M.

In: Expert Review of Clinical Pharmacology, Vol. 2, No. 6, 01.12.2009, p. 619-630.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Finding the place of histone deacetylase inhibitors in prostate cancer therapy

AU - Marrocco-Tallarigo, Deborah L.

AU - Centenera, Margaret M.

AU - Scher, Howard I.

AU - Tilley, Wayne D.

AU - Butler, Lisa M.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological malignancies and solid tumors. In the case of prostate cancer, HDACIs are effective at inhibiting proliferation and inducing apoptosis in a range of in vitro and in vivo experimental models. Recent studies have revealed that the actions of HDACIs in prostate cancer cells extend beyond regulation of histone acetylation and affect proteins involved in maintaining cellular homeostasis and tumor progression, including the androgen receptor, p21WAF1 and VEGF. The broad spectrum of HDACI targets has allowed rational design of combinations with other therapeutic agents to target multiple pathways involved in prostate cancer progression, including angiogenesis and androgen signaling. In particular, synergistic inhibition of prostate cancer cell growth has been demonstrated using HDACIs in combination with radio- and chemo-therapy, Apo2L/TRAIL, angiogenesis inhibitors, heat-shock protein 90 inhibitors and androgen receptor antagonists. This review examines the current understanding of the actions of HDACIs in prostate cancer cells, both in a laboratory and a clinical context and discusses the potential utility of combination strategies for the treatment of prostate cancer.

AB - Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological malignancies and solid tumors. In the case of prostate cancer, HDACIs are effective at inhibiting proliferation and inducing apoptosis in a range of in vitro and in vivo experimental models. Recent studies have revealed that the actions of HDACIs in prostate cancer cells extend beyond regulation of histone acetylation and affect proteins involved in maintaining cellular homeostasis and tumor progression, including the androgen receptor, p21WAF1 and VEGF. The broad spectrum of HDACI targets has allowed rational design of combinations with other therapeutic agents to target multiple pathways involved in prostate cancer progression, including angiogenesis and androgen signaling. In particular, synergistic inhibition of prostate cancer cell growth has been demonstrated using HDACIs in combination with radio- and chemo-therapy, Apo2L/TRAIL, angiogenesis inhibitors, heat-shock protein 90 inhibitors and androgen receptor antagonists. This review examines the current understanding of the actions of HDACIs in prostate cancer cells, both in a laboratory and a clinical context and discusses the potential utility of combination strategies for the treatment of prostate cancer.

KW - Androgen signaling

KW - Clinical trials

KW - Combination therapies

KW - Histone deacetylase inhibitors

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=70549095136&partnerID=8YFLogxK

U2 - 10.1586/ecp.09.44

DO - 10.1586/ecp.09.44

M3 - Review article

VL - 2

SP - 619

EP - 630

JO - Expert Review of Clinical Pharmacology

T2 - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 6

ER -